Theratome Bio Invested 2016

Theratome Bio is developing a portfolio of therapeutics derived from the secretome of adult stem cells for conventional therapy options. Its lead product Thera-101 is an injectable biologic drug designed to be first-line therapy for ischemic brain injury, including stroke. First-in-human clinical trial of Thera-101 is in progress.